Clinical Trial Update: Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SyB L-0501 in Relapsed/Refractory Multiple Myeloma; the study has completed and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SyB L-0501

Snippet

Sponsor: SymBio Pharmaceuticals | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2015-01-09